KBC Group’s Haemonetics HAE Stock Holding History

KBC Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$106K	Hold	1,419	–	–	﹤0.01%	1382
2026 Q1	$80K	Hold	1,419	–	–	﹤0.01%	1455
2025 Q4	$114K	Hold	1,419	–	–	﹤0.01%	1199
2025 Q3	$69K	Hold	1,419	–	–	﹤0.01%	1491
2025 Q2	$106K	Sell	1,419 -998	-41%	-$66.1K	﹤0.01%	1164
2025 Q1	$154K	Buy	2,417 +401	+20%	+$27.3K	﹤0.01%	1228
2024 Q4	$157K	Buy	2,016 +712	+55%	+$57.2K	﹤0.01%	1273
2024 Q3	$105K	Hold	1,304	–	–	﹤0.01%	1253
2024 Q2	$108K	Buy	1,304 +235	+22%	+$20.7K	﹤0.01%	1119
2024 Q1	$91K	Hold	1,069	–	–	﹤0.01%	1171
2023 Q4	$91K	Hold	1,069	–	–	﹤0.01%	1111
2023 Q3	$96K	Buy	+1,069	New	+$95.4K	﹤0.01%	1026
2018 Q4	–	Sell	-13,520	Closed	-$1.55M	–	1337
2018 Q3	$1.55M	Hold	13,520	–	–	0.01%	776
2018 Q2	$1.21M	Buy	+13,520	New	+$1.14M	0.01%	745
2013 Q3	–	Sell	-143	Closed	-$6K	–	1268
2013 Q2	$6K	Buy	+143	New	+$5.79K	﹤0.01%	1232

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's HAE Position: Q2 2026 in Review

KBC Group held its Haemonetics (HAE) position steady in Q2 2026 at 1,419 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1382.

KBC Group first reported a position in HAE in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.55M in Q3 2018. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

KBC Group held 1,419 shares of Haemonetics worth $106K as of Q2 2026.
KBC Group left its Haemonetics share count unchanged in Q2 2026.
Haemonetics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1382 holding.
KBC Group first reported a position in Haemonetics in Q2 2013 and has held it in 15 quarters since.
KBC Group's Haemonetics position peaked at $1.55M in Q3 2018.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.